NVCT
Nuvectis Pharma, Inc.- Healthcare
- Biotechnology
- $637M market cap
Forecast run · Sep 14, 2026Upside rank 101 of 3,136
Model Signal
ForecastQ Daily Probabilities
73.3%
58.1%
56.0%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$23.99
Price target$37.33
Implied move+55.6%
Analysts3
ForecastQ Portfolios
NVCT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.